---
title: "Nabriva Therapeutics plc (NBRVF.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NBRVF.US.md"
symbol: "NBRVF.US"
name: "Nabriva Therapeutics plc"
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:45:44.333Z"
locales:
  - [en](https://longbridge.com/en/quote/NBRVF.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NBRVF.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NBRVF.US.md)
---

# Nabriva Therapeutics plc (NBRVF.US)

## Company Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.nabriva.com](https://www.nabriva.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.75)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 176 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -16.35% |  |
| Net Profit YoY | -18.12% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 323.08 |  |
| Revenue | 29557000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -602.21% | E |
| Profit Margin | -186.26% | E |
| Gross Margin | -352.96% | E |
| Revenue YoY | -16.35% | E |
| Net Profit YoY | -18.12% | D |
| Total Assets YoY | -80.73% | E |
| Net Assets YoY | -147.16% | E |
| Cash Flow Margin | 23.45% | D |
| OCF YoY | -16.35% | E |
| Turnover | 0.90 | A |
| Gearing Ratio | 254.29% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Nabriva Therapeutics plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-16.35%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.12%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "323.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "29557000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-602.21%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-186.26%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-352.96%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-16.35%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.12%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-80.73%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-147.16%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "23.45%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-16.35%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.90",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "254.29%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NBRVF.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NBRVF.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NBRVF.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**